2022 World Conference on Lung Cancer (ePosters)-EP08.01-037. Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy

EP08.01-037. Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy

Back to course

Pdf Summary

A study conducted at the Rush University Medical Center in Chicago aimed to evaluate the outcomes of stage IV non-small cell lung cancer (NSCLC) patients treated with immunotherapy (IO) alone versus a combination of immunotherapy and chemotherapy (IO/CT). The study found that patients who received IO/CT had better progression-free survival (PFS) compared to those who received IO alone. This was evident at 3 months and 6 months after treatment initiation. However, there was no significant difference in overall survival (OS) between the two treatment groups.<br /><br />The study also analyzed the impact of baseline factors, specifically high pre-treatment neutrophil-lymphocyte ratio (NLR) and low body mass index (BMI), on survival outcomes. It was observed that patients with a baseline NLR of 5 who received IO alone had significantly worse OS, PFS, and early PFS at 3 months compared to patients with a NLR greater than 5. This difference was not observed in patients treated with IO/CT. Similarly, a baseline BMI of 20 was associated with worse prognosis in the IO alone group compared to the IO/CT group.<br /><br />The study highlights the need for accessible clinical markers that can identify non-responders to IO monotherapy before treatment initiation. While current practice limits IO monotherapy to patients with high programmed death-ligand 1 (PDL1) expression, further evaluation of NLR as a biomarker in treated patients with known levels of tumor PD-L1 expression is recommended.<br /><br />In conclusion, the combination of immunotherapy and chemotherapy shows improved survival outcomes, particularly in patients with a baseline NLR of 5 or low BMI. The study suggests the potential usefulness of NLR and BMI as prognostic markers in NSCLC patients receiving immunotherapy. Further research is required to validate these findings and determine the optimal treatment strategies for individual patients.

Asset Subtitle

Hita Moudgalya

Meta Tag

Speaker Hita Moudgalya

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Rush University Medical Center

stage IV non-small cell lung cancer

NSCLC

immunotherapy

chemotherapy

progression-free survival

overall survival

neutrophil-lymphocyte ratio

body mass index

clinical markers